Navigation Links
DaVita Launches 'Flu Fighter Program' in Support of National Influenza Week
Date:12/10/2008

EL SEGUNDO, Calif., Dec. 10 /PRNewswire-FirstCall/ -- DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney failure and disease (CKD), continues to push the Flu Fighters initiative which takes place during the month of December to complement the events of National Influenza Week, Dec. 8 - 14.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

The National Influenza Week kicks off this week and is designed to raise awareness of the importance of continuing influenza (flu) vaccination, as well as foster greater use of flu vaccine in December, January, and beyond.

DaVita(R) strives to educate every patient on the benefits of the flu vaccine and hopes to ensure at least 90 percent of patients at every center get vaccinated. Vaccination is one of the most effective interventions available to save lives and prevent hospitalization in dialysis patients. Dialysis patients who already suffer from End Stage Renal Disease are at high risk for the flu, and DaVita hopes this initiative will combat those odds.

Allen R. Nissenson, MD, Chief Medical Officer at DaVita said, "Each year more than 200,000 people are hospitalized for influenza-related complications. Influenza vaccinations are of the highest clinical focus in our company. We want our patients to be as healthy as possible and vaccinations are an opportunity to prevent illness before it starts. It is just one more way to provide for quality patient care and put our patients first."

The flu vaccinations are available at no cost to all DaVita patients and are covered by Medicare. The DaVita Flu Fighters immunization standards are in sync with the Centers for Medicare and Medicaid Services initiative called Healthy People 2010. DaVita expects that more than 90 percent of its patients, as well as direct patient case employees, will be vaccinated to decrease the chances of spreading disease across the dialysis center and to optimize the health of its patients.

DaVita is a registered trademarks of DaVita Inc. All other trademarks are the properties of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages more than 1,400 outpatient facilities and acute units in more than 700 hospitals located in 43 states and the District of Columbia, serving approximately 110,000 patients. As part of DaVita's commitment to building a healthy, caring community, DaVita develops, participates in and donates to numerous programs dedicated to transforming communities and creating positive, sustainable change for children, families and our environment. For more information about DaVita, its kidney education materials, and its community programs, please visit http://www.davita.com.


'/>"/>
SOURCE DaVita Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike
2. Superior Patient Clinical Outcomes Confirms DaVitas Leadership Position on Quality Dialysis Care
3. Third Annual DaVita Kidney Disease Awareness Walks to Hit 20 Cities in 2008
4. DaVita Introduces Treatment Evaluator
5. DaVita Honored for 4th Year as Training Top 125 Recipient
6. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
7. NxStage Medical Announces Needle Supply Agreement with DaVita
8. DaVita to Present at UBS Best of Americas Conference
9. Techstreet Launches BuildingBlocks Utility for Industry Standards Saving Time and Increasing Productivity for Engineers
10. Axial Biotech Launches Genetic Test for Adolescent Idiopathic Scoliosis (AIS)
11. Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):